303 related articles for article (PubMed ID: 20519671)
1. Read-through strategies for suppression of nonsense mutations in Duchenne/ Becker muscular dystrophy: aminoglycosides and ataluren (PTC124).
Finkel RS
J Child Neurol; 2010 Sep; 25(9):1158-64. PubMed ID: 20519671
[TBL] [Abstract][Full Text] [Related]
2. Phase 2a study of ataluren-mediated dystrophin production in patients with nonsense mutation Duchenne muscular dystrophy.
Finkel RS; Flanigan KM; Wong B; Bönnemann C; Sampson J; Sweeney HL; Reha A; Northcutt VJ; Elfring G; Barth J; Peltz SW
PLoS One; 2013; 8(12):e81302. PubMed ID: 24349052
[TBL] [Abstract][Full Text] [Related]
3. Read-through approach for stop mutations in Duchenne muscular dystrophy. An update.
Politano L
Acta Myol; 2021 Mar; 40(1):43-50. PubMed ID: 33870095
[TBL] [Abstract][Full Text] [Related]
4. [Treatment with antisense oligonucleotides in Duchenne's disease].
Pascual-Pascual SI
Rev Neurol; 2012 May; 54 Suppl 3():S31-9. PubMed ID: 22605630
[TBL] [Abstract][Full Text] [Related]
5. Ataluren and aminoglycosides stimulate read-through of nonsense codons by orthogonal mechanisms.
Ng MY; Li H; Ghelfi MD; Goldman YE; Cooperman BS
Proc Natl Acad Sci U S A; 2021 Jan; 118(2):. PubMed ID: 33414181
[TBL] [Abstract][Full Text] [Related]
6. Gentamicin treatment of Duchenne and Becker muscular dystrophy due to nonsense mutations.
Wagner KR; Hamed S; Hadley DW; Gropman AL; Burstein AH; Escolar DM; Hoffman EP; Fischbeck KH
Ann Neurol; 2001 Jun; 49(6):706-11. PubMed ID: 11409421
[TBL] [Abstract][Full Text] [Related]
7. Emerging genetic therapies to treat Duchenne muscular dystrophy.
Nelson SF; Crosbie RH; Miceli MC; Spencer MJ
Curr Opin Neurol; 2009 Oct; 22(5):532-8. PubMed ID: 19745732
[TBL] [Abstract][Full Text] [Related]
8. In vitro read-through of phenylalanine hydroxylase (PAH) nonsense mutations using aminoglycosides: a potential therapy for phenylketonuria.
Ho G; Reichardt J; Christodoulou J
J Inherit Metab Dis; 2013 Nov; 36(6):955-9. PubMed ID: 23532445
[TBL] [Abstract][Full Text] [Related]
9. [Therapeutic readthrough strategy for suppression of nonsense mutations in duchenne muscular dystrophy].
Shiozuka M; Matsuda R
Brain Nerve; 2011 Nov; 63(11):1253-60. PubMed ID: 22068478
[TBL] [Abstract][Full Text] [Related]
10. Early treatment with Ataluren of a 2-year-old boy with nonsense mutation Duchenne dystrophy.
Bitetti I; Mautone C; Bertella M; Manna MR; Varone A
Acta Myol; 2021 Dec; 40(4):184-186. PubMed ID: 35047759
[TBL] [Abstract][Full Text] [Related]
11. Ataluren treatment of patients with nonsense mutation dystrophinopathy.
Bushby K; Finkel R; Wong B; Barohn R; Campbell C; Comi GP; Connolly AM; Day JW; Flanigan KM; Goemans N; Jones KJ; Mercuri E; Quinlivan R; Renfroe JB; Russman B; Ryan MM; Tulinius M; Voit T; Moore SA; Lee Sweeney H; Abresch RT; Coleman KL; Eagle M; Florence J; Gappmaier E; Glanzman AM; Henricson E; Barth J; Elfring GL; Reha A; Spiegel RJ; O'donnell MW; Peltz SW; Mcdonald CM;
Muscle Nerve; 2014 Oct; 50(4):477-87. PubMed ID: 25042182
[TBL] [Abstract][Full Text] [Related]
12. The functional mechanisms and clinical application of read-through drugs.
Fu Y; Shu ZY; Gu MM
Yi Chuan; 2016 Jul; 38(7):623-633. PubMed ID: 27733335
[TBL] [Abstract][Full Text] [Related]
13. PTC124, nonsense mutations and Duchenne muscular dystrophy.
Wilton S
Neuromuscul Disord; 2007 Oct; 17(9-10):719-20. PubMed ID: 17952895
[No Abstract] [Full Text] [Related]
14. Ataluren: first global approval.
Ryan NJ
Drugs; 2014 Sep; 74(14):1709-14. PubMed ID: 25193627
[TBL] [Abstract][Full Text] [Related]
15. Meta-analyses of ataluren randomized controlled trials in nonsense mutation Duchenne muscular dystrophy.
Campbell C; Barohn RJ; Bertini E; Chabrol B; Comi GP; Darras BT; Finkel RS; Flanigan KM; Goemans N; Iannaccone ST; Jones KJ; Kirschner J; Mah JK; Mathews KD; McDonald CM; Mercuri E; Nevo Y; Péréon Y; Renfroe JB; Ryan MM; Sampson JB; Schara U; Sejersen T; Selby K; Tulinius M; Vílchez JJ; Voit T; Wei LJ; Wong BL; Elfring G; Souza M; McIntosh J; Trifillis P; Peltz SW; Muntoni F; ; ;
J Comp Eff Res; 2020 Oct; 9(14):973-984. PubMed ID: 32851872
[No Abstract] [Full Text] [Related]
16. European Medicines Agency review of ataluren for the treatment of ambulant patients aged 5 years and older with Duchenne muscular dystrophy resulting from a nonsense mutation in the dystrophin gene.
Haas M; Vlcek V; Balabanov P; Salmonson T; Bakchine S; Markey G; Weise M; Schlosser-Weber G; Brohmann H; Yerro CP; Mendizabal MR; Stoyanova-Beninska V; Hillege HL
Neuromuscul Disord; 2015 Jan; 25(1):5-13. PubMed ID: 25497400
[No Abstract] [Full Text] [Related]
17. Reading through premature stop codons with PTC1 24. Project Catalyst to find more Duchenne drugs. Interview by Guenter Scheuerbrandt.
Welch E; Goetz D; Almstead N
Acta Myol; 2008 Oct; 27():63-8. PubMed ID: 19364064
[No Abstract] [Full Text] [Related]
18. Readthrough strategies for stop codons in Duchenne muscular dystrophy.
Aurino S; Nigro V
Acta Myol; 2006 Jun; 25(1):5-12. PubMed ID: 17039975
[TBL] [Abstract][Full Text] [Related]
19. [Mutation-specific treatments for Duchenne muscular dystrophy].
Matsuo M; Takeshima Y
Brain Nerve; 2009 Aug; 61(8):915-22. PubMed ID: 19697880
[TBL] [Abstract][Full Text] [Related]
20. Continuitiy of care with ataluren in Duchenne Muscular Dystrophy patients with nonsense mutations after loss of ambulation. Personal experience.
Spagnoli C; Adorisio R; Bello L; D'Amico A; D'Angelo MG; Pane M; Penzo M; Riguzzi P; Sansone V; Vianello A; Fusco C
Acta Myol; 2023; 42(4):118-122. PubMed ID: 38406379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
